<code id='BF6353D65A'></code><style id='BF6353D65A'></style>
    • <acronym id='BF6353D65A'></acronym>
      <center id='BF6353D65A'><center id='BF6353D65A'><tfoot id='BF6353D65A'></tfoot></center><abbr id='BF6353D65A'><dir id='BF6353D65A'><tfoot id='BF6353D65A'></tfoot><noframes id='BF6353D65A'>

    • <optgroup id='BF6353D65A'><strike id='BF6353D65A'><sup id='BF6353D65A'></sup></strike><code id='BF6353D65A'></code></optgroup>
        1. <b id='BF6353D65A'><label id='BF6353D65A'><select id='BF6353D65A'><dt id='BF6353D65A'><span id='BF6353D65A'></span></dt></select></label></b><u id='BF6353D65A'></u>
          <i id='BF6353D65A'><strike id='BF6353D65A'><tt id='BF6353D65A'><pre id='BF6353D65A'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:53148
          Nasdaq
          Mario Tama/Getty Images

          Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

          The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

          advertisement

          The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex
          Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

          IsnoonesafefromtheFTC?HasPfizerbottomedout?Andisbiotechfinallyback?Wecoverallthatandmorethisweekon“T

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Doudna institute plans to 'cure hundreds of diseases' with CRISPR

          ChristineKao/STATResearchersattendinggenetherapymeetingsoverthepastcoupleyearswereliabletobumpintoas